Last reviewed · How we verify
RX-10045
At a glance
| Generic name | RX-10045 |
|---|---|
| Sponsor | C.T. Development America, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery (PHASE2)
- A Study of RX-10045 in the Treatment of Dry Eye Disease (PHASE2)
- Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis (PHASE2)
- Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RX-10045 CI brief — competitive landscape report
- RX-10045 updates RSS · CI watch RSS
- C.T. Development America, Inc. portfolio CI